SEC Form 4 · accession 0001209191-15-074184
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stuart A Arbuckle
Officer — EVP\Chief Commercial Officer
Period of report
Oct 1, 2015
Accepted (ET)
Oct 5, 2015 · 8:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Oct 1, 2015 | S | 700 | $102.30 | D | 126,815 | D | |
| Common StockF3,F4 | Oct 1, 2015 | S | 900 | $103.28 | D | 125,915 | D | |
| Common StockF3,F5 | Oct 1, 2015 | S | 5,159 | $104.45 | D | 120,756 | D | |
| Common StockF3,F6 | Oct 1, 2015 | S | 5,058 | $105.41 | D | 115,698 | D | |
| Common StockF3,F7 | Oct 1, 2015 | S | 600 | $106.07 | D | 115,098 | D | |
| Common Stock | holding | — | — | — | 140 | I | 401(k) |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $102.30 (range $101.68 to $102.66).
- F3Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $103.28 (range $102.71 to $103.60).
- F5Open market sales reported on this line occurred at a weighted average price of $104.45 (range $103.89 to $104.88).
- F6Open market sales reported on this line occurred at a weighted average price of $105.41 (range $104.91 to $105.90).
- F7Open market sales reported on this line occurred at a weighted average price of $106.07 (range $105.99 to $106.12).